Ushashi Banerjee

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Combination Therapy

Candida Albicans

Top Venues

Science advances

Molecular omics

This page only lists publications with an associated author ORCID identifier.

Publications

Ushashi Banerjee, Salik Miskat Borbora, Madhura Guha, Vikas Yadav, V Sanjay, Amit Singh, Kithiganahalli Narayanaswamy Balaji, Nagasuma Chandra
Inhibition of leukotriene-B4 signalling-mediated host response to tuberculosis is a potential mode of adjunctive host-directed therapy. Immunology (2024)
Ushashi Banerjee, Salik Miskat Borbora, Madhura Guha, Vikas Yadav, V Sanjay, Amit Singh, Kithiganahalli Narayanaswamy Balaji, Nagasuma Chandra
Inhibition of leukotriene-B4 signalling-mediated host response to tuberculosis is a potential mode of adjunctive host-directed therapy. Immunology 172 (3) (2024)
Ushashi Banerjee, Salik Miskat Borbora, Madhura Guha, Vikas Yadav, V Sanjay, Amit Singh, Kithiganahalli Narayanaswamy Balaji, Nagasuma Chandra
Inhibition of leukotriene-B4 signalling-mediated host response to tuberculosis is a potential mode of adjunctive host-directed therapy. Immunology 172 (3) (2024)
Mayashree Das, Sreesa Sreedharan, Somnath Shee, Nitish Malhotra, Meghna Nandy, Ushashi Banerjee, Sakshi Kohli, Raju S Rajmani, Nagasuma Chandra, Aswin Sai Narain Seshasayee, Sunil Laxman, Amit Singh
Cysteine desulfurase (IscS)-mediated fine-tuning of bioenergetics and SUF expression prevents Mycobacterium tuberculosis hypervirulence. Science advances 9 (50) (2023)
Ushashi Banerjee, Pragati Rao, Megha Reddy, Meeran Hussain, Sneha Chunchanur, R Ambica, Amit Singh, Nagasuma Chandra
A 9-gene biomarker panel identifies bacterial coinfections in culture-negative COVID-19 cases. Molecular omics 18 (8) (2022)